1
|
Hayashida K, Hirayama S, Iwai T, Watanabe Y, Takahashi T, Sakai J, Nakata E, Yamakawa T, Fujii H, Nagase H. Novel delta opioid receptor agonists with oxazatricyclodecane structure showing potent agonistic activities. Bioorg Med Chem Lett 2017; 27:2742-2745. [DOI: 10.1016/j.bmcl.2017.04.059] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Revised: 04/15/2017] [Accepted: 04/18/2017] [Indexed: 11/30/2022]
|
2
|
Loriga G, Lazzari P, Manca I, Ruiu S, Falzoi M, Murineddu G, Bottazzi MEH, Pinna G, Pinna GA. Novel diazabicycloalkane delta opioid agonists. Bioorg Med Chem 2015; 23:5527-38. [DOI: 10.1016/j.bmc.2015.07.036] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 07/17/2015] [Accepted: 07/19/2015] [Indexed: 12/19/2022]
|
3
|
Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists. Bioorg Med Chem Lett 2015; 25:2927-30. [DOI: 10.1016/j.bmcl.2015.05.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Revised: 05/13/2015] [Accepted: 05/18/2015] [Indexed: 11/21/2022]
|
4
|
Fujii H, Hayashida K, Saitoh A, Yokoyama A, Hirayama S, Iwai T, Nakata E, Nemoto T, Sudo Y, Uezono Y, Yamada M, Nagase H. Novel delta opioid receptor agonists with oxazatricyclodecane structure. ACS Med Chem Lett 2014; 5:368-72. [PMID: 24900842 DOI: 10.1021/ml400491k] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Accepted: 01/27/2014] [Indexed: 11/28/2022] Open
Abstract
We synthesized compounds 4a,c-f,h,i containing the oxazatricyclodecane structure from a novel rearrangement reaction product 2a. All the prepared compounds 4a,c-f,h,i exhibited full agonistic activities for the δ opioid receptor (DOR). Among them, the N-methyl derivative 4c was highly selective, and the most effective DOR agonist in functional assays. Subcutaneous administration of 4c produced dose-dependent and NTI (selective DOR antagonist)-reversible antinociception lacking any convulsive behaviors in the mice acetic acid writhing tests. The N-methyl derivative 4c is expected to be a promising lead compound for selective DOR agonists with a novel chemotype.
Collapse
Affiliation(s)
- Hideaki Fujii
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Kohei Hayashida
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Akiyoshi Saitoh
- Department
of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, Tokyo 187-8553, Japan
| | - Akinobu Yokoyama
- Division
of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Tokyo 104-0045, Japan
- Faculty
of Pharmaceutical Science, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 274-8510, Japan
| | - Shigeto Hirayama
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Takashi Iwai
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Eriko Nakata
- Discovery
Research Laboratories, Nippon Chemiphar Co., Ltd., 1-22 Hikokawado, Misato, Saitama 341-0005, Japan
| | - Toru Nemoto
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Yuka Sudo
- Division
of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Tokyo 104-0045, Japan
- Faculty
of Pharmaceutical Science, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 274-8510, Japan
| | - Yasuhito Uezono
- Division
of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Tokyo 104-0045, Japan
| | - Mitsuhiko Yamada
- Department
of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashimachi, Kodaira, Tokyo 187-8553, Japan
| | - Hiroshi Nagase
- School
of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| |
Collapse
|
5
|
Loriga G, Lazzari P, Ruiu S, Marchese G, Manca I, Casu GL, Dessì C, Pinna GA, Asproni B, Murineddu G. Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons. Eur J Med Chem 2013; 69:413-26. [PMID: 24090913 DOI: 10.1016/j.ejmech.2013.09.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 09/03/2013] [Accepted: 09/05/2013] [Indexed: 12/01/2022]
Abstract
Considering the interesting pharmacological profile of the delta (δ) selective opioid agonist compound SNC-80, conformationally constrained analogs containing two diazatricyclodecane ring systems in place of dimethylpiperazine core motif were synthesized. The compounds showed subnanomolar or low nanomolar δ opioid receptor binding affinity. Depending upon the substituents on the diazatricyclodecane ring, these compounds displayed varying selectivity for δ opioid receptor over μ and κ receptors. Amongst the novel compounds, 1Aa showed the more interesting biological profile, with higher δ affinity and selectivity compared to SNC-80. The δ receptor agonist profile and antinociceptive activity of 1Aa were confirmed using ex-vivo (isolated mouse vas deferens) and in vivo (tail flick) assays.
Collapse
Affiliation(s)
- Giovanni Loriga
- C.N.R. Istituto di Farmacologia Traslazionale, UOS Cagliari, Edificio 5, Loc. Piscinamanna, 09010 Pula, CA, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fujii H, Takahashi T, Nagase H. Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012). Expert Opin Ther Pat 2013; 23:1181-208. [DOI: 10.1517/13543776.2013.804066] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
7
|
Nonpeptidic Delta (δ) Opioid Agonists and Antagonists of the Diarylmethylpiperazine Class: What Have We Learned? Top Curr Chem (Cham) 2010; 299:121-40. [DOI: 10.1007/128_2010_83] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
8
|
Holl R, Jung B, Schepmann D, Humpf HU, Grünert R, Bednarski P, Englberger W, Wünsch B. Synthesis and Pharmacological Evaluation of SNC80 Analogues with a Bridged Piperazine Ring. ChemMedChem 2009; 4:2111-22. [DOI: 10.1002/cmdc.200900358] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
9
|
3D Quantitative and Qualitative Structure-Activity Relationships of the δ -Opioid Receptor Antagonists. B KOREAN CHEM SOC 2008. [DOI: 10.5012/bkcs.2008.29.3.656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Metcalf MD, Coop A. 5'-halogenated analogs of oxymorphindole. Bioorg Med Chem Lett 2007; 17:5916-7. [PMID: 17826993 PMCID: PMC2062523 DOI: 10.1016/j.bmcl.2007.07.098] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2007] [Revised: 07/23/2007] [Accepted: 07/25/2007] [Indexed: 11/22/2022]
Abstract
The presence of a 6,7-fused indole group in the indolomorphinans was considered to be responsible for the delta opioid selectivity for this class of ligands. Herein is shown that 5'-halogenated analogs of oxymorphindole are opioids with little selectivity for delta receptors over mu opioid receptors.
Collapse
Affiliation(s)
- Matthew D Metcalf
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA
| | | |
Collapse
|
11
|
Bernard D, Coop A, MacKerell AD. Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity. J Med Chem 2007; 50:1799-809. [PMID: 17367120 PMCID: PMC2631547 DOI: 10.1021/jm0612463] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Recent studies have indicated several therapeutic applications for delta opioid agonists and antagonists. To exploit the therapeutic potential of delta opioids developing a structural basis for the activity of ligands at the delta opioid receptor is essential. The conformationally sampled pharmacophore (CSP) method (Bernard et al. J. Am. Chem. Soc. 2003, 125, 3103-3107) is extended here to obtain quantitative models of delta opioid ligand efficacy and affinity. Quantification is performed via overlap integrals of the conformational space sampled by ligands with respect to a reference compound. Iterative refinement of the CSP model identified hydrophobic groups other than the traditional phenylalanine residues as important for efficacy and affinity in DSLET and ICI 174 864. The obtained models for a structurally diverse set of peptidic and nonpeptidic delta opioid ligands offer good predictions with R2 values>0.9, and the predicted efficacy for a set of test compounds was consistent with the experimental values.
Collapse
Affiliation(s)
| | | | - Alexander D. MacKerell
- * Corresponding author: Room 629, HSF II, 20 Penn Street, Baltimore MD 21201, , Tel: 410-706-7442, Fax: 410-706-5017
| |
Collapse
|
12
|
Cheng K, Kim IJ, Lee MJ, Adah SA, Raymond TJ, Bilsky EJ, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Rothman RB, Jacobson AE, Rice KC. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Org Biomol Chem 2007; 5:1177-1190. [PMID: 17406716 DOI: 10.1039/b618875c] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Enantiomeric N-phenethyl-m-hydroxyphenylmorphans with various substituents in the ortho, meta or para positions of the aromatic ring in the phenethylamine side-chain (chloro, hydroxy, methoxy, nitro, methyl), as well as a pyridylethyl and a indolylethyl moiety on the nitrogen atom, were synthesized and their binding affinity to the mu-, delta-, and kappa-opioid receptors was examined. The higher affinity ligands were further examined in the [(35)S]GTPgammaS assay to study their function and efficacy. 3-((1R,5S)-(-)-2-(4-Nitrophenethyl)-2-aza-bicyclo[3.3.1]nonan-5-yl)phenol ((-)-) was found to be a mu-agonist and delta-antagonist in that functional assay and was about 50 fold more potent than morphine in vivo. 3-((1R,5S)-(-)-2-(4-Chlorophenethyl)-2-aza-bicyclo[3.3.1]nonan-5-yl)phenol ((-)-) and several other ligands displayed inverse agonist activity at the delta-opioid receptor. The absolute configuration of all of the reported compounds was established by chemical conversion of (-)- to 1R,5S-(-)-.HBr.
Collapse
MESH Headings
- Animals
- Binding, Competitive/drug effects
- CHO Cells
- Cricetinae
- Cricetulus
- Ligands
- Morphinans/chemical synthesis
- Morphinans/chemistry
- Morphinans/pharmacology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/chemistry
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/chemistry
- Stereoisomerism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Kejun Cheng
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| | - In Jong Kim
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| | - Mei-Jing Lee
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| | - Steven A Adah
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| | - Tyler J Raymond
- University of New England, College of Osteopathic Medicine, Biddeford, ME 04005, USA
| | - Edward J Bilsky
- University of New England, College of Osteopathic Medicine, Biddeford, ME 04005, USA
| | - Mario D Aceto
- Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Everette L May
- Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Louis S Harris
- Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Andrew Coop
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
| | - Christina M Dersch
- Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, USA
| | - Richard B Rothman
- Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland 21224, USA
| | - Arthur E Jacobson
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| | - Kenner C Rice
- Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
| |
Collapse
|
13
|
Le Bourdonnec B, Goodman AJ, Michaut M, Ye HF, Graczyk TM, Belanger S, Herbertz T, Yap GPA, DeHaven RN, Dolle RE. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists. J Med Chem 2007; 49:7278-89. [PMID: 17149858 DOI: 10.1021/jm060486f] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The series of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines have been widely investigated as opioid receptor antagonists. One of our research goals was to explore the bioactive conformation of the N-phenethyl trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine derivative 3, prototypical mu-opioid antagonist in this series. In this effort, the rotational degrees of freedom of the N-substituent of 3 were limited by incorporation of an ethylene bridge between the piperidine 2- or 6-position of 3 and the benzylic position of the N-phenethyl moiety. The overall modification led to a novel series of fused bicyclic derivatives of the octahydroquinolizine chemical class, conformationally restricted analogue of 3. The constrained analogues 6 and 9 showed high affinity toward the mu-opioid receptor. Compound 6 was found to be a mu-opioid antagonist, whereas the constrained analogue 9 displayed potent mu-agonist activity in vitro. This study provides additional information about the molecular determinants for mu recognition, the structural features affecting ligand binding, and the structure function relationships.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Akgün E, Portoghese PS, Sajjad M, Nabi HA. Synthesis and124I-labeling ofm-iodophenylpyrrolomorphinan as a potential PET imaging agent for delta opioid (DOP) receptors. J Labelled Comp Radiopharm 2007. [DOI: 10.1002/jlcr.1216] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
15
|
Thomas JB, Zhang L, Navarro HA, Carroll FI. Highly Potent and Selective Phenylmorphan-Based Inverse Agonists of the Opioid δ Receptor. J Med Chem 2006; 49:5597-609. [PMID: 16942033 DOI: 10.1021/jm060459p] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We recently reported the discovery of (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl-(1-phenyl-1-cyclopentane)carboxamide [(+)-KF4, (+)-5] as a novel chemotype possessing potent antagonist activity at the delta opioid receptor. Additional SAR studies involving changes to both the 2-amino and 7-amido N-substituents using this same (+)-morphan scaffold have revealed compounds with improved potency and selectivity for the delta opioid receptor. The highly potent and selective 2,2-dimethylphenylacetamide analogue (+)-N-[(1S,4R,5R,7S)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl]-2-methyl-2-phenylpropanamide (13d, delmorphan-A) showed picomolar inhibitory potency (Ke = 0.1 nM) in the [35S]GTPgammaS functional assay with delta opioid receptor selectivity ratios of 103- and 132-fold versus the mu and kappa opioid receptors, respectively. The compounds showed no agonist activity at any of the three opioid receptors; however, measurements of delta inverse agonist activity within this series illustrated a broad range of negative efficacy and IC50 values 650-fold more potent than the prototypical delta opioid receptor inverse agonist ICI 174,864 (22).
Collapse
Affiliation(s)
- James B Thomas
- Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709, USA
| | | | | | | |
Collapse
|
16
|
Trabanco AA, Pullan S, Alonso JM, Alvarez RM, Andrés JI, Boeckx I, Fernández J, Gómez A, Iturrino L, Janssens FE, Leenaerts JE, De Lucas AI, Matesanz E, Meert T, Steckler T. 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists. Bioorg Med Chem Lett 2006; 16:146-9. [PMID: 16236510 DOI: 10.1016/j.bmcl.2005.09.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2005] [Revised: 09/06/2005] [Accepted: 09/12/2005] [Indexed: 01/01/2023]
Abstract
A novel series of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives has been prepared and their synthesis described herein. In vitro affinities for delta-, mu-, and kappa-opioid receptors, as well as the functional activity in the [(35)S]GTPgammaS assay are reported. The most potent and selective delta-opioid agonist 18a exhibited a K(i) of 18 nM, and was >258-fold and 28-fold selective over mu- and kappa-receptors, respectively; the compound is a full agonist with an EC(50) value of 14 nM.
Collapse
Affiliation(s)
- Andrés A Trabanco
- Division of Psychiatry, Research and Early Development Europe, Johnson and Johnson Pharmaceutical Research and Development, Jarama 75, 47007 Toledo, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Jung B, Englberger W, Wünsch B. Molecular modeling directed synthesis of a bicyclic analogue of the δ opioid receptor agonist SNC 80. Arch Pharm (Weinheim) 2005; 338:281-90. [PMID: 15938001 DOI: 10.1002/ardp.200400994] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In order to find novel delta opioid receptor agonists, the pharmacophoric benzhydryl moiety of the lead compound SNC 80 (1) was dissected and the phenyl residues were attached to different positions of the 6,8-diazabicyclo[3.2.2]nonane core system (4). The position of the carboxamido group, the stereochemistry, the C3/C4 bond order and the kind and length of the spacer X were considered. The resulting compounds were compared with the four energetically most favourable conformations of SNC 80 by a multifit analysis. These calculations led to the structures 5-10, which fit best to SNC 80. Herein the synthesis of one of these compounds (9) is described. Starting from (S)-glutamate two alternative routes are detailed to obtain the key intermediate 14. A variation of the Dieckmann cyclization, which uses trapping of the first cyclization product with ClSiMe(3) provided the mixed acetal 20, which was carefully hydrolyzed to yield the bicyclic ketone 17. Stereoselective addition of phenylmagnesium bromide, dehydration, LiAlH(4) reduction and exchange of the N-6 residue afforded the designed compound 9. The affinities of 9 towards delta, mu, kappa and ORL1 receptors were determined in receptor binding studies with radioligands. Only moderate receptor affinity was found.
Collapse
Affiliation(s)
- Bettina Jung
- Institut für Pharmazeutische und Medizinische Chemie, Münster, Germany
| | | | | |
Collapse
|
18
|
Clarke RW. Synaptic mechanisms in nociception: emerging targets for centrally-acting analgesics. ACTA ACUST UNITED AC 2005. [DOI: 10.1517/14728222.4.2.173] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
19
|
Carson JR, Coats SJ, Codd EE, Dax SL, Lee J, Martinez RP, Neilson LA, Pitis PM, Zhang SP. N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists. Bioorg Med Chem Lett 2004; 14:2109-12. [PMID: 15080989 DOI: 10.1016/j.bmcl.2004.02.051] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2003] [Accepted: 02/10/2004] [Indexed: 11/30/2022]
Abstract
A series of N,N-dialkyl-4-(9-aryltropanylidenemethyl)benzamides was prepared. The lead compounds, 15a and 15c, exhibited extremely high affinity for the delta opioid receptor with excellent selectivity versus the micro opioid receptor. They were full agonists at the delta opioid receptor, as assessed by stimulation of GTPgammaS binding, and displayed antinociceptive activity.
Collapse
Affiliation(s)
- John R Carson
- Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, Welsh and McKean Roads, PO 776, Spring House, PA 19477-0776, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Srivastava SK, Shefali S, Miller CN, Aceto MD, Traynor JR, Lewis JW, Husbands SM. Effects of Substitution on the Pyrrole N Atom in Derivatives of Tetrahydronaltrindole, Tetrahydrooxymorphindole, and a Related 4,5-Epoxyphenylpyrrolomorphinan. J Med Chem 2004; 47:6645-8. [PMID: 15588100 DOI: 10.1021/jm040817t] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The effect of substitution of the pyrrolo- and indolo-N atoms in tetrahydronaltrindole (TNTI), tetrahydrooxymorphindole (TOMI), and 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-4'-phenyl-6,7:2',3'-pyrrolomorphinan (4) is reported. In opioid functional assays 4 were potent deltaopioid receptor (DOR) antagonists while the TNTI derivatives (7) were potent DOR antagonists or low-efficacy DOR partial agonists without substantial selectivity. The TOMI derivatives (8) were DOR agonists with significant selectivity. In vivo the DOR antagonist activity of 7d was confirmed, but the predominant agonist effect of 8d was shown to be mu opioid receptor mediated.
Collapse
MESH Headings
- Analgesics/chemical synthesis
- Analgesics/chemistry
- Analgesics/pharmacology
- Animals
- Binding, Competitive
- CHO Cells
- Cricetinae
- Cricetulus
- Humans
- Indoles/chemical synthesis
- Indoles/chemistry
- Indoles/pharmacology
- Ligands
- Morphinans/chemical synthesis
- Morphinans/chemistry
- Morphinans/pharmacology
- Naltrexone/analogs & derivatives
- Naltrexone/chemical synthesis
- Naltrexone/chemistry
- Naltrexone/pharmacology
- Radioligand Assay
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, kappa/antagonists & inhibitors
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Sanjay K Srivastava
- Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, U.K
| | | | | | | | | | | | | |
Collapse
|
21
|
Coats SJ, Schulz MJ, Carson JR, Codd EE, Hlasta DJ, Pitis PM, Stone DJ, Zhang SP, Colburn RW, Dax SL. Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists. Bioorg Med Chem Lett 2004; 14:5493-8. [PMID: 15482911 DOI: 10.1016/j.bmcl.2004.09.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2004] [Revised: 09/01/2004] [Accepted: 09/03/2004] [Indexed: 11/18/2022]
Abstract
Two parallel synthetic methods were developed to explore the structure-activity relationships (SAR) of a series of potent opioid agonists. This series of tropanylidene benzamides proved extremely tolerant of structural variation while maintaining excellent opioid activity. Evaluation of several representative compounds from this series in the mouse hot plate test revealed potent antinociceptive effects upon oral administration.
Collapse
Affiliation(s)
- Steven J Coats
- Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Welsh and McKean Roads, PO Box 776, Spring House, PA 19477-0776, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Carroll FI, Zhang L, Mascarella SW, Navarro HA, Rothman RB, Cantrell BE, Zimmerman DM, Thomas JB. Discovery of the First N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)morphan To Possess Highly Potent and Selective Opioid δ Receptor Antagonist Activity. J Med Chem 2003; 47:281-4. [PMID: 14711299 DOI: 10.1021/jm030419a] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A structurally novel opioid delta receptor selective antagonist has been identified. This compound, (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl-(1-phenyl-1-cyclopentane)carboxamide [(+)-KF4, (+)-4], showed a K(e) value of 0.15 nM in the [(35)S]GTPgammaS functional assay. (+)-KF4 is also a delta inverse agonist with an IC(50) value of 1.8 nM. To our knowledge, this is the first potent and selective delta opioid receptor antagonist from the 5-phenylmorphan class of opioids.
Collapse
Affiliation(s)
- F Ivy Carroll
- Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Kim IJ, Ullrich T, Janetka JW, Furness MS, Jacobson AE, Rothman RB, Dersch CM, Flippen-Anderson JL, George C, Rice KC. Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide and (−)-4-[(αR)-α-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide. Bioorg Med Chem 2003; 11:4761-8. [PMID: 14556791 DOI: 10.1016/s0968-0896(03)00496-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We have explored the synthesis of compounds that have good affinity for both mu- and delta-opioid receptors from the (alphaR,2S,5S) class of diaryldimethylpiperazines. These non-selective compounds were related to opioids that have been found to interact selectively with mu- or delta-opioid receptors as agonists or antagonists. In our initial survey, we found two compounds, (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide (14) and its N-H relative, (-)-4-[(alphaR)-alpha-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide (15), that interacted with delta-receptors with good affinity, and, as we hoped, with much higher affinity at mu-receptors than SNC80. The relative configuration of the benzylic position in (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethyl-1-piperazinyl)-(3-methoxyphenyl)methyl]-benzyl alcohol (10) was determined by X-ray crystallographic analysis of a crystal that was an unresolved twin. The absolute stereochemistry of that benzylic stereogenic center was unequivocally derived by the X-ray crystallographic analysis from the two other centers of asymmetry in the molecule that were known. Those were established from the synthesis via a dipeptide cyclo-L-Ala-L-Ala in which the absolute stereochemistry was established.
Collapse
MESH Headings
- Animals
- Benzamides/chemical synthesis
- Benzamides/chemistry
- Benzamides/metabolism
- Benzamides/pharmacology
- Brain/metabolism
- Cell Membrane/metabolism
- Crystallography, X-Ray
- Guinea Pigs
- Ligands
- Molecular Conformation
- Molecular Structure
- Piperazines/chemical synthesis
- Piperazines/chemistry
- Piperazines/metabolism
- Piperazines/pharmacology
- Radioligand Assay
- Rats
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/metabolism
- Stereoisomerism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- In Jong Kim
- Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Marie N, Landemore G, Debout C, Jauzac P, Allouche S. Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci 2003; 73:1691-704. [PMID: 12875901 DOI: 10.1016/s0024-3205(03)00489-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We investigated the pharmacological properties of a newly synthesised delta agonist AR-M1000390, derived from SNC-80 ((+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethyl-benzamide), in the neuroblastoma cell line SK-N-BE expressing only human delta-opioid receptors. Binding and functional experiments showed a weak affinity (K(i) = 106 +/- 34 nM) correlated with a weak potency (EC(50) = 111 +/- 31 nM) to inhibit the forskolin-stimulated cAMP accumulation. Sustained activation of opioid receptors in the presence of the maximal inhibitory concentration of AR-M1000390 produced a rapid and strong desensitization. In order to examine the contribution of internalization and down-regulation in the desensitization processes, binding and functional experiments were conducted in the presence or in the absence of hypertonic sucrose solution to block clathrin-dependent opioid receptor endocytosis. We observed both the inability of AR-M1000390 to down-regulate opioid receptors and the absence of any effect of sucrose on desensitization. The lack of delta-opioid receptor internalization by AR-M1000390 was further corroborated by confocal microscopy using antibodies directed either against the endogenous delta-opioid receptors or the FLAG-tagged delta-opioid receptors stably expressed in the SK-N-BE cells. These data suggest that uncoupling rather than internalization is responsible for delta-opioid receptors desensitization by AR-M1000390.
Collapse
Affiliation(s)
- Nicolas Marie
- Laboratoire de Pharmacologie moléculaire de la tolérance aux opiacés, Université de Caen, Caen, France
| | | | | | | | | |
Collapse
|
25
|
Carroll FI. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J Med Chem 2003; 46:1775-94. [PMID: 12723940 DOI: 10.1021/jm030092d] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- F Ivy Carroll
- Chemistry and Life Sciences Group, Research Triangle Institute, P.O. Box 12194, Research Triangle Park, North Carolina 27709, USA.
| |
Collapse
|
26
|
Bernard D, Coop A, MacKerell AD. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists. J Am Chem Soc 2003; 125:3101-7. [PMID: 12617677 DOI: 10.1021/ja027644m] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Pharmacophores are widely used for rational drug design and include those based on receptor binding sites or on known ligands. To date, ligand-based pharmacophores have typically used one or a small number of conformers of known receptor ligands. However, this method does not take into account the inherent dynamic nature of molecules, which sample a wide range of conformations, any of which could be the bound form. In the present study, molecular dynamics (MD) simulations were used as a means to sample the conformational space of ligands to include all accessible conformers at room temperature in the development of a pharmacophore. On the basis of these conformers, probability distributions of selected distances and angles in a series of delta specific opioid ligands were obtained and correlated with agonist versus antagonist activities. Individually, the distributions did not allow for unique agonist and antagonist pharmacophores to be identified. However, by extending the conformational analysis to two dimensions, a 2D conformationally sampled pharmacophore (CSP) for distinguishing delta receptor agonists and antagonists was developed. Application of this model to the compound DPI2505 suggests that it may have agonist activity. It is anticipated that the CSP method, which does not require alignment of compounds during pharmacophore development, will be a useful tool for obtaining structure-function relationships of ligands particularly in systems where the receptor 3D structure is not known.
Collapse
Affiliation(s)
- Denzil Bernard
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201, USA
| | | | | |
Collapse
|
27
|
Verotta L, Orsini F, Sbacchi M, Scheildler MA, Amador TA, Elisabetsky E. Synthesis and antinociceptive activity of chimonanthines and pyrrolidinoindoline-type alkaloids. Bioorg Med Chem 2002; 10:2133-42. [PMID: 11983509 DOI: 10.1016/s0968-0896(02)00078-0] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Hodgkinsine, a trimeric pyrrolidinoindoline type alkaloid, present as a major constituent of Psychotria spp. (Rubiaceae), has shown to produce dose-dependent, naloxone reversible, analgesic effect in thermal models of nociception and in the capsaicin-induced pain. SAR studies have been initiated by synthesizing the three diastereomeric dimers (chimonanthines) (11-13) which were evaluated in vitro and in vivo along with the synthetic intermediates. Strong binding affinities for mu opioid receptors were found for (-)- and (+)-chimonanthine monourethanes (9 and 10), whereas (-)-, (+)- and (meso)-chimonanthine (11-13) and hodgkinsine displayed low affinity. In vivo data have shown that only (+)-chimonanthine (12) and calycosidine resemble the analgesic profile found for hodgkinsine.
Collapse
Affiliation(s)
- L Verotta
- Dipartimento di Chimica Organica e Industriale, Università degli Studi di Milano,via Venezian 21, 20133 Milan, Italy.
| | | | | | | | | | | |
Collapse
|
28
|
Ullrich T, Dersch CM, Rothman RB, Jacobson AE, Rice KC. Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. Bioorg Med Chem Lett 2001; 11:2883-5. [PMID: 11597422 DOI: 10.1016/s0960-894x(01)00580-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In an effort to establish the importance of the N-(2-methylallyl) substituent in the noroxymorphone series, several derivatives have been synthesized, retaining that N-substituent and modifying the delta address moiety. A few compounds showed moderate binding affinity and selectivity for the delta receptor; none displayed a pharmacological profile as exceptional as N-(2-methylallyl)noroxymorphindole. A second study showed that 3-O-methylation of all derivatives decreases binding affinity. The present results indicate that only a combination of the N-(2-methylallyl) group and an indole delta address provided high selectivity for the delta receptor.
Collapse
Affiliation(s)
- T Ullrich
- Laboratory of Medicinal Chemistry, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | |
Collapse
|
29
|
Thomas JB, Herault XM, Rothman RB, Atkinson RN, Burgess JP, Mascarella SW, Dersch CM, Xu H, Flippen-Anderson JL, George CF, Carroll FI. Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides. J Med Chem 2001; 44:972-87. [PMID: 11300879 DOI: 10.1021/jm000427g] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A study of the effect of transposition of the internal nitrogen atom for the adjacent benzylic carbon atom in delta-selective agonists such as BW373U86 (1) and SNC-80 (2) has been undertaken. It was shown that high-affinity, fully efficacious, and delta opioid receptor-selective compounds can be obtained from this transposition. In addition to the N,N-diethylamido group needed as the delta address, the structural features identified to promote delta receptor affinity in the set of compounds studied included a cis relative stereochemistry between the 3- and 4-substituents in the piperidine ring, a trans-crotyl or allyl substituent on the basic nitrogen, the lack of a 2-methyl group in the piperidine ring, and either no substitution or hydroxyl substitution in the aryl ring not substituted with the N,N-diethylamido group. Structural features found to be important for mu affinity include hydroxyl substitution in the aryl ring, the presence of a 2-methyl group in a cis relative relationship to the 4-amino group as well as N-substituents such as cyclopropylmethyl. It was also determined that mu receptor affinity could be increased while maintaining delta receptor affinity, especially when hydroxyl-substituted compounds are considered. Additionally, it was discovered that the somewhat lower mu/delta selectivities observed for the piperidine compounds relative to the piperazine-based ligands appear to arise as a consequence of the carbon-nitrogen transposition which imparts an overall lower delta and higher mu affinity to the piperidine-based ligands. This higher affinity for the mu receptor, apparently intrinsic to the piperidine-based compounds, suggests that ligands of this class will more easily be converted to mu/delta combination agonists compared to the piperazine ligands such as 1. This is particularly important since analogues of 1, which show both mu- and delta-type activity, are now recognized as important for their strong analgesia and cross-canceling of many of the side effects found in agonists operating exclusively from either the delta or mu opioid receptor.
Collapse
Affiliation(s)
- J B Thomas
- Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
This paper is the twenty-second installment of the annual review of research concerning the opiate system. It summarizes papers published during 1999 that studied the behavioral effects of the opiate peptides and antagonists, excluding the purely analgesic effects, although stress-induced analgesia is included. The specific topics covered this year include stress; tolerance and dependence; learning, memory, and reward; eating and drinking; alcohol and other drugs of abuse; sexual activity, pregnancy, and development; mental illness and mood; seizures and other neurologic disorders; electrical-related activity; general activity and locomotion; gastrointestinal, renal, and hepatic function; cardiovascular responses; respiration and thermoregulation; and immunologic responses.
Collapse
Affiliation(s)
- A L Vaccarino
- Department of Psychology, University of New Orleans, New Orleans, LA 70148, USA.
| | | |
Collapse
|
31
|
Coop A, Jacobson AE, Aceto MD, Harris LS, Traynor JR, Woods JH, Rice KC. N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole. Bioorg Med Chem Lett 2000; 10:2449-51. [PMID: 11078198 DOI: 10.1016/s0960-894x(00)00479-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The position of the indole in the indolomorphinans, which includes the delta opioid antagonist naltrindole, is considered to be responsible for the delta opioid selectivity for this class of ligands. Herein is described the N-cyclohexylethyl substituted N-nor-derivative, which is shown to be mu preferring. Thus, the nature of the N-substituent is equally important to the receptor selectivity for this class of ligands.
Collapse
Affiliation(s)
- A Coop
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore 21201, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Plobeck N, Delorme D, Wei ZY, Yang H, Zhou F, Schwarz P, Gawell L, Gagnon H, Pelcman B, Schmidt R, Yue SY, Walpole C, Brown W, Zhou E, Labarre M, Payza K, St-Onge S, Kamassah A, Morin PE, Projean D, Ducharme J, Roberts E. New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability. J Med Chem 2000; 43:3878-94. [PMID: 11052793 DOI: 10.1021/jm000228x] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Nonpeptide delta opioid agonists are analgesics with a potentially improved side-effect and abuse liability profile, compared to classical opioids. Andrews analysis of the NIH nonpeptide lead SNC-80 suggested the removal of substituents not predicted to contribute to binding. This approach led to a simplified lead, N, N-diethyl-4-[phenyl(1-piperazinyl)methyl]benzamide (1), which retained potent binding affinity and selectivity to the human delta receptor (IC(50) = 11 nM, mu/delta = 740, kappa/delta > 900) and potency as a full agonist (EC(50) = 36 nM) but had a markedly reduced molecular weight, only one chiral center, and increased in vitro metabolic stability. From this lead, the key pharmacophore groups for delta receptor affinity and activation were more clearly defined by SAR and mutagenesis studies. Further structural modifications on the basis of 1 confirmed the importance of the N, N-diethylbenzamide group and the piperazine lower basic nitrogen for delta binding, in agreement with mutagenesis data. A number of piperazine N-alkyl substituents were tolerated. In contrast, modifications of the phenyl group led to the discovery of a series of diarylmethylpiperazines exemplified by N, N-diethyl-4-[1-piperazinyl(8-quinolinyl)methyl]benzamide (56) which had an improved in vitro binding profile (IC(50) = 0.5 nM, mu/delta = 1239, EC(50) = 3.6 nM) and increased in vitro metabolic stability compared to SNC-80.
Collapse
MESH Headings
- Animals
- Benzamides/chemical synthesis
- Benzamides/chemistry
- Benzamides/metabolism
- Biological Availability
- Cell Line
- Chromatography, High Pressure Liquid
- Humans
- In Vitro Techniques
- Mass Spectrometry
- Microsomes, Liver/metabolism
- Piperazines/chemical synthesis
- Piperazines/chemistry
- Piperazines/metabolism
- Quinolines/chemical synthesis
- Quinolines/chemistry
- Quinolines/metabolism
- Radioligand Assay
- Rats
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/metabolism
- Stereoisomerism
- Structure-Activity Relationship
- Thermodynamics
- Transfection
Collapse
Affiliation(s)
- N Plobeck
- Departments of Chemistry and Pharmacology, AstraZeneca R&D Montreal, 7171 Frederick-Banting, Saint-Laurent, Quebec, Canada H4S 1Z9.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Maeda DY, Coop A. Studies into the Direct Conversion of Indolomorphinans to their 4-Phenolic Derivatives. Tetrahedron 2000. [DOI: 10.1016/s0040-4020(00)00667-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Thomas JB, Atkinson RN, Rothman RB, Burgess JP, Mascarella SW, Dersch CM, Xu H, Carroll FI. 4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity. Bioorg Med Chem Lett 2000; 10:1281-4. [PMID: 10866400 DOI: 10.1016/s0960-894x(00)00209-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The tropane derived compounds, 4-[(8-alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-d iethylbenzamides (5a-d), were synthesized and found to have high affinity and selectivity for the delta receptor. Compounds 5a-d are structurally similar to the full agonist (-)-RTI-5989-54 (3); yet, efficacy studies for compounds in this series (5a-d) reveal greatly diminished agonist activity as well as antagonism not found in piperidine-based compounds like 3.
Collapse
Affiliation(s)
- J B Thomas
- Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Boyd RE, Carson JR, Codd EE, Gauthier AD, Neilson LA, Zhang SP. Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists. Bioorg Med Chem Lett 2000; 10:1109-11. [PMID: 10843229 DOI: 10.1016/s0960-894x(00)00182-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
A series of 4-diarylaminotropanes has been prepared. Both endo and exo diastereomeric forms bound to the delta opioid receptor but the endo isomers were more potent and selective versus the mu opioid receptor than the exo isomers. The most potent delta opioid agonist (14) exhibited a delta opioid Ki of 0.2 nM and was 860-fold selective over mu.
Collapse
MESH Headings
- Animals
- Benzamides/metabolism
- Binding Sites
- Diphenylamine/analogs & derivatives
- Diphenylamine/chemistry
- Diphenylamine/metabolism
- Diphenylamine/pharmacology
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/metabolism
- Enkephalin, D-Penicillamine (2,5)-/metabolism
- Morphine/metabolism
- Piperazines/metabolism
- Rats
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/metabolism
- Stereoisomerism
- Structure-Activity Relationship
- Tropanes/chemistry
- Tropanes/metabolism
- Tropanes/pharmacology
Collapse
Affiliation(s)
- R E Boyd
- Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Spring House, Philadelphia, PA 19477, USA
| | | | | | | | | | | |
Collapse
|
36
|
Alfaro-Lopez J, Okayama T, Hosohata K, Davis P, Porreca F, Yamamura HI, Hruby VJ. Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. J Med Chem 1999; 42:5359-68. [PMID: 10639279 DOI: 10.1021/jm990337f] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
SL-3111 [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] is a de novo designed, high-affinity and selective nonpeptide peptidomimetic agonist of the delta-opioid receptor. In a previous report we had described the unique biological characteristics of this ligand and also a need for further structural evaluation.(6) To pursue this, we have introduced a completely different heterocyclic template (2 and 3), which, based on molecular modeling studies, may present the required structural features to properly orient the pharmacophore groups. We also have made more subtle changes to the original piperazine scaffold (5 and 11). The biological activities of these compounds revealed an important participation of the scaffold in the ligand-receptor interaction. To further explore functional diversity on the scaffold, we have maintained the original piperazine ring and introduced four different functionalities at position 2 of the heterocyclic ring (15a-d; a = CH(2)-O-CH(2)-Ph; b = Me; c = CH(2)Ph; d = CH(2)OH). The biological activities observed for these compounds showed a very interesting trend in terms of the steric effects of the groups introduced at this position. A decrease of almost 2000-fold in affinity and potency at the delta-receptor was observed for 15c compared with 15b. This difference may be explained if we postulate that the bioactive conformation of these peptidomimetics is close to the minimal energy conformations calculated in our study. On the basis of these findings we have realized the importance of this position to further explore and simplify the structure of future generations of peptidomimetic ligands.
Collapse
Affiliation(s)
- J Alfaro-Lopez
- Department of Chemistry, The University of Arizona, Tucson, Arizona 85721, USA
| | | | | | | | | | | | | |
Collapse
|